Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
187 hedge funds and large institutions have $1.52B invested in Global Blood Therapeutics, Inc. in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 75 increasing their positions, 49 reducing their positions, and 30 closing their positions.
410% more call options, than puts
Call options by funds: $44.8M | Put options by funds: $8.79M
53% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 49
7% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 30
2% less funds holding
Funds holding: 191 → 187 (-4)
33% less capital invested
Capital invested by funds: $2.25B → $1.52B (-$734M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$23.7M |
| 3 |
CC
Casdin Capital
New York
|
+$18.1M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$12.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$127M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$42.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$41M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$16.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.4M |
GBT Hedge Fund Activity: Q3 2021 in Review
187 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2021, worth a combined $1.52B — down 33% from $2.25B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of GBT and 28 opened new positions — a net loss of 2 holders — while 49 trimmed existing stakes and 75 added.
The largest buyer was Fidelity Investments, adding an estimated $45.9M. The largest seller was Bank of America, cutting an estimated $127M.
- 187 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2021, down from 191 in Q2 2021.
- Funds reported $1.52B of Global Blood Therapeutics, Inc. stock for Q3 2021, down 33% quarter-over-quarter.
- 28 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2021 and 30 closed out, a net change of -2 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2021 was Fidelity Investments, an estimated $45.9M added.
- The largest Global Blood Therapeutics, Inc. seller in Q3 2021 was Bank of America, an estimated $127M sold.
Based on aggregated 13F filings for Q3 2021.